跳至主要内容
临床试验/NCT01232322
NCT01232322已完成不适用

Pulmicort Respules 0.25/0.5 Specific Clinical Experience Investigation for Long-term Use in Pediatrics

AstraZeneca0 个研究点目标入组 633 人开始时间: 2006年10月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
633
主要终点
Incidence of Adverse Events

研究概览

简要总结

The purpose of this study is to investigate the safety and efficacy for long term treatment of the drug in children aged 6 months and < 5 years on bronchial asthma in daily clinical usage.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
6 Months 至 5 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Patients treated with Pulmicort Respules for the first time due to bronchial asthma
  • Children of >= 6 months and < 5 years old age at the start of study treatment

排除标准

  • 未提供

结局指标

主要结局

Incidence of Adverse Events

时间窗: Range of 3 years

Effects on growth rate

时间窗: Range of 3 years

Variation of the height/weight from the baseline.

Effects on the adrenal cortical function.

时间窗: Range of 3 years

Symptoms of adrenal cortical function suppression before and after the treatment with Pulmicort.

Effects on development of infections.

时间窗: Range of 3 years

Existence and type of infections.

次要结局

  • Clinical course under Pulmicort long-term use

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

相似试验

Pulmicort Respules 0.25/0.5 Specific Clinical... | 临床试验